Drug Data Roughs Up Relypsa Inc (RLYP)

New user growth for Relypsa Inc's (RLYP) hyperkalemia drug, Veltassa, slowed in April

May 17, 2016 at 10:45 AM
facebook X logo linkedin


Relypsa Inc (NASDAQ:RLYP) dropped as much as 7.8% this morning after the drugmaker reported a decline in the number of new patients taking its hyperkalemia drug, Veltassa, last month. Adding insult to injury, Citigroup lowered its price target on the stock to $25 from $30. However, the pharmaceutical stock has managed to pare its losses, down 2.5% at $14.45 at last check -- and options traders are counting on a further recovery.

Despite Citigroup's price-target cut, overall, the brokerage crowd is mostly upbeat toward RLYP. Eight analysts currently maintain "strong buy" ratings on the stock, versus one "hold" and two "strong sells." Not to mention, the shares' consensus 12-month price target of $31.75 registers in territory not charted since early August.

It's much the same in the options pits, where roughly 10 calls have been bought to open for each put during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Echoing this, RLYP's Schaeffer's put/call open interest ratio (SOIR) of 0.37 ranks in the bottom quartile of its annual range, with short-term calls nearly tripling puts.

Whether that optimism is warranted is another story altogether. Since hitting a recent top at $25.60 in early April, Relypsa Inc (NASDAQ:RLYP) has plummeted 43.6%. This technical bloodbath has provoked more than a fair share of short selling. In fact, 41.6% of the stock's float is sold short, which translates to 5.8 times RLYP's average daily trading levels. What's more, it's possible some of the recent call buyers are short sellers seeking protection against an unexpected rally.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI